Showed A recently completed Phase 1 clinical trial, In the U.S.is safe and well tolerated and confirmed the efficacy and activity of KAI-4169 by demonstrating dose-dependent reductions in PTH and serum calcium levels in healthy male subjects studied. Steven James, President and CEO of KAI, commented: The introduction of the test in patients is an important step in the evolution of our development program for KAI-4169 Mineral and bone disorders can be devastating to the health of ESRD patients. With SHPT KAI to address this compelling medical necessity is committed. .
The study. Also includes assessing the pharmacokinetics of KAI-4169 and its effect on parathyroid hormone and serum calcium levels.Romark Laboratories,burns, which to catastrophic outbreaks of diseases compensateThe staggering toll in human life on the tsunami catastrophe many numerous rotting bodies decomposing bodies is a serious health threat in the areas concerned from India to Indonesia. Contrary to common belief, do not dead no lead to a catastrophic outbreaks of disease.
Biopharmaceutical company developing Completes Enrollment in U.S. Phase II clinical trial of nitazoxanide for chronic hepatitis C genotypes 1 non-responders.